Saquinavir
FDA-approved product (capsule, oral), marketed as Fortovase, Invirase.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- HIV infection
- HIV-1 infection
- Viral disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Protease inhibitors
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE01
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae33.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis71.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Saquinavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Nafarelin AcetateExisting use: Endometriosis58.6% AI-predicted activityagainst E. coli12 registered studies
- Goserelin AcetateExisting use: Breast cancer, Breast carcinoma, Carcinoma and 1 more58.5% AI-predicted activityagainst E. coli50+ registered studies
- Doxazosin MesylateExisting use: Benign prostatic hyperplasia, Hypertension, Myocardial infarction58.3% AI-predicted activityagainst E. coli50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more58.1% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder57.8% AI-predicted activityagainst E. coliNo documented evidence found
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction57.4% AI-predicted activityagainst E. coli1 registered study
- Trametinib Dimethyl SulfoxideExisting use: Cancer, Cutaneous melanoma, Glioblastoma multiforme and 5 more57.2% AI-predicted activityagainst E. coli16 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma57.2% AI-predicted activityagainst E. coli50+ registered studies
- Cisapride MonohydrateExisting use: Gastrointestinal disease56.3% AI-predicted activityagainst E. coli5 registered studies
- Prazosin HydrochlorideExisting use: Diabetes mellitus, Hypertension56.3% AI-predicted activityagainst E. coli50+ registered studies
- PemigatinibExisting use: Cancer, Cholangiocarcinoma, Neoplasm56.0% AI-predicted activityagainst E. coli50+ registered studies
- AtogepantExisting use: Migraine disorder56.0% AI-predicted activityagainst E. coli36 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
The Safety and Effectiveness of Two Forms of Saquinavir Combined With Other Anti-HIV Drugs in HIV-Infected Infants and Children
NCT00002380
Registered record
- Registry ID
- NCT00002380
- Conditions
- HIV Infections
- Interventions
- Nelfinavir mesylate; Saquinavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionNelfinavir mesylate; SaquinavirPhasePhase 1Registry statusCompletedA Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients
NCT00002383
Registered record
- Registry ID
- NCT00002383
- Conditions
- HIV Infections
- Interventions
- Saquinavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionSaquinavirPhasePhase 1Registry statusCompletedThe Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs
NCT00002425
Registered record
- Registry ID
- NCT00002425
- Conditions
- HIV Infections
- Interventions
- Saquinavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionSaquinavirPhasePhase 4Registry statusCompletedSafety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV
NCT00084058
Registered record
- Registry ID
- NCT00084058
- Conditions
- HIV Infections
- Interventions
- Lopinavir/ritonavir; Saquinavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 2006-12
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionLopinavir/ritonavir; SaquinavirPhasePhase 1 / Phase 2Registry statusCompletedA Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy
NCT00102206
Registered record
- Registry ID
- NCT00102206
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate; Emtricitabine; Lamivudine; Lopinavir/ritonavir; Saquinavir; Tenofovir disoproxil fumarate; Zidovudine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 2007-05
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionAbacavir sulfate; Emtricitabine; Lamivudine; Lopinavir/ritonavir +3 morePhasePhase 2Registry statusCompleted